Pro Football Hall of Famer and Cancer Survivor Jim Kelly Joins Merck to Challenge America to Raise Funds for the Cancer Community

30-day Your Cancer Game Plan Challenge Helps Those Impacted by Cancer and the Patient Organizations That Support Them
Feb 2, 2018 3:25 PM ET

Learn More About Your Cancer Game Plan Challenge

With an estimated 1.6 million Americans diagnosed in 2017 alone, cancer not only impacts those diagnosed but their friends and family as well. In recognition of World Cancer Day on Sunday, Feb. 4, Merck (NYSE: MRK), known as MSD outside the United States and Canada, along with Pro Football Hall of Famer Jim Kelly is asking all Americans to join the Your Cancer Game Plan Challenge, a social awareness effort to help raise funds to support cancer patient organizations. The 30-day effort kicked off today as part of Your Cancer Game Plan, a comprehensive resource from Merck and the cancer advocacy community, to help cancer survivors and their loved ones manage the emotional, health and communication challenges of a cancer journey.

About Merck

For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.